Publicaciones en colaboración con investigadores/as de Charles University in Prague (8)

2021

  1. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

    Atherosclerosis

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

2016

  1. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

    European Heart Journal, Supplement, Vol. 18, pp. C2-C12

  2. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases

    European Heart Journal, Vol. 37, Núm. 23, pp. 1850-1858

2015

  1. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy

    Atherosclerosis Supplements, Vol. 19, pp. 1-12

2013

  1. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

    European Heart Journal, Vol. 34, Núm. 28, pp. 2159-2219

  2. Post hoc analysis of the cluster randomized usual care versus caduet Investigation Assessing Long-term Risk (CRUCIAL) trial

    Current Medical Research and Opinion, Vol. 29, Núm. 6, pp. 589-596

2007

  1. Cardiac manifestations of Anderson-Fabry disease: Results from the international Fabry outcome survey

    European Heart Journal, Vol. 28, Núm. 10, pp. 1228-1235